Squarepoint
KLRS icon

Squarepoint’s Kalaris Therapeutics KLRS Stock Holding History

Squarepoint’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$54.8K Sell
18,947
-19,828
-51% -$76.7K ﹤0.01% 4280
2026
Q2 		$158K Sell
38,775
-998
-3% -$5.18K ﹤0.01% 4116
2026
Q1 		$229K Buy
39,773
+14,406
+57% +$128K ﹤0.01% 3886
2025
Q4 		$214K Sell
25,367
-14,806
-37% -$94.7K ﹤0.01% 3822
2025
Q3 		$232K Sell
40,173
-18,922
-32% -$62.5K ﹤0.01% 3846
2025
Q2 		$158K Buy
59,095
+44,508
+305% +$201K ﹤0.01% 4050
2025
Q1 		$117K Sell
14,587
-106
-0.7% -$1.04K ﹤0.01% 4181
2024
Q4 		$142K Buy
+14,693
New +$222K ﹤0.01% 4589
2024
Q1 		– Sell
-12,397
Closed -$194K – 4722
2023
Q4 		$194K Buy
12,397
+9,682
+357% +$382K ﹤0.01% 3607
2023
Q3 		$134K Sell
2,715
-1,437
-35% -$97.9K ﹤0.01% 3513
2023
Q2 		$325K Buy
4,152
+954
+30% +$90.7K ﹤0.01% 2918
2023
Q1 		$290K Buy
3,198
+38
+1% +$4.84K ﹤0.01% 2593
2022
Q4 		$373K Buy
+3,160
New +$536K ﹤0.01% 2458
2022
Q3 		– Sell
-738
Closed -$66K – 3541
2022
Q2 		$66K Sell
738
-489
-40% -$51.3K ﹤0.01% 2681
2022
Q1 		$190K Buy
1,227
+562
+85% +$112K ﹤0.01% 2492
2021
Q4 		$198K Buy
+665
New +$308K ﹤0.01% 2708
2021
Q3 		– Sell
-950
Closed -$431K – 3535
2021
Q2 		$431K Buy
+950
New +$491K ﹤0.01% 2253

Other funds holding KLRS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Belpointe Asset Management
Belpointe Asset Management Reno, Nevada $3.63B AUM 17.81% 1-Year Est. Return
Fortis Capital Advisors
Fortis Capital Advisors Prairie Village, Kansas $1.3B AUM 27.43% 1-Year Est. Return
WealthTrust Asset Management
WealthTrust Asset Management Destin, Florida $181M AUM 17.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Strengthening Families & Communities LLC
Strengthening Families & Communities LLC Boston, Massachusetts $459M AUM 29.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint's KLRS Position: Q3 2026 in Review

Squarepoint reduced its Kalaris Therapeutics (KLRS) stake by 51% in Q3 2026, selling an estimated $76.7K and leaving 18,947 shares worth $54.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4280.

Squarepoint first reported a position in KLRS in Q2 2021 and has held it in 17 quarters since. The position peaked at $431K in Q2 2021. 14 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.

  • Squarepoint held 18,947 shares of Kalaris Therapeutics worth $54.8K as of Q3 2026.
  • Squarepoint sold 19,828 Kalaris Therapeutics shares in Q3 2026, an estimated $76.7K.
  • Kalaris Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4280 holding.
  • Squarepoint first reported a position in Kalaris Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • Squarepoint's Kalaris Therapeutics position peaked at $431K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.